India s market cap has reached an impressive $4 trillion, reflecting a market cap to GDP ratio of 1.2, indicating stretched valuations. Despite this, short-term market movements are expected to outpace fundamentals. The recent surge to record highs has been propelled by Foreign Institutional Investors (FIIs) turning buyers for five consecutive days while Domestic Institutional Investors (DIIs) continuing their buying. Positive exit poll results further fuelled this upward momentum, creating a distinctly bullish market sentiment.
On Thursday, 1898 stocks advanced, 1810 declined and 149 remained unchanged, with an advance decline ratio of 1.04 on the Bombay Stock Exchange (BSE), indicating positive closing of stocks in broader markets.
Aurobindo unit gets USFDA nod to market generic asthma medication thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.
Aurobindo Pharma promoters have begun the process of selling a majority stake in its injectables business, Eugia Pharma Specialities, after negotiations with potential suitors failed to meet valuation expectations. The promoters have hired investment bank Moelis to manage the sale.
Aurobindo Pharma has undergone a significant reorganisation, restructuring its operations into three subsidiaries. Eugia Pharma Specialities is dedicated to injectables and specialty oral solid dosages; Curateq Biologics focusing on vaccines, biosimilars, and peptides; Apitoria Pharma, an API division.